As a pathophysiologically-relevant APP α-secretase [12], many AD symptom-attenuating effects of experimental manipulations and drugs/compounds have been attributed to an enhancement of α-secretase-based APP processing, some of which are directly linked to ADAM10 activity [31,32,33,34,35]. This evidence concerns the gene ADAM10 and Alzheimer disease.